{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '82', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.2', 'Other Allowed Dose Interruptions', 'Pembrolizumab may be interrupted for situations other than treatment-related AEs, such as', 'medical/surgical events or logistical reasons not related to study therapy. Participants should', 'be placed back on study therapy within 3 weeks of the scheduled interruption, unless', 'otherwise discussed with the Sponsor. The reason for interruption should be documented in', \"the participant's study record. Scans should not be delayed for delays in cycle treatment.\", '6.7', 'Intervention After the End of the Study', 'There is no study-specified intervention after the end of the study.', '6.8', 'Clinical Supplies Disclosure', 'NOTE: As of Amendment 007-06, the study is unblinded and this section is no longer', 'applicable.', '6.9', 'Standard Policies', 'At the close of the study after unblinding, a letter is to be sent by the investigator to those', \"participants who received placebo in the image of the competitor's product to provide the\", 'following advice:', '\"You have participated in a study conducted by the Sponsor. This letter is to advise you that', 'you were among those who received a look-alike capsule provided by the Sponsor to', 'resemble the drug lenvatinib as much as possible. You did not receive the active drug', 'lenvatinib as provided by Merck.\"', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT', 'WITHDRAWAL', '7.1', 'Discontinuation of Study Intervention', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study and participants stopped receiving those. This section has been updated', 'accordingly.', 'Discontinuation of study intervention does not represent withdrawal from the study.', 'As certain data on clinical events beyond study intervention discontinuation may be', \"important to the study, they must be collected through the participant's last scheduled follow-\", 'up, even if the participant has discontinued study intervention. Therefore, all participants', 'who discontinue study intervention prior to completion of the protocol-specified treatment', 'period will still continue to participate in the study as specified in Sections 1.3 and 8.11.4', 'unless the participant has withdrawn from the study (Section 7.2).', 'Participants may discontinue study intervention at any time for any reason or be discontinued', 'from the study intervention at the discretion of the investigator should any untoward effect', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '83', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'occur. In addition, a participant may be discontinued from study intervention by the', 'investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or', 'for administrative and/or other safety reasons. Specific details regarding procedures to be', 'performed at study intervention discontinuation are provided in Sections 8.1.9 and 8.11.4.', 'A participant must be discontinued from study intervention but continue to be monitored in', 'the study for any of the following reasons:', \"The participant or participant's legally acceptable representative requests to\", 'discontinue study intervention.', 'The participant interrupts study intervention administration for more than 12 weeks,', 'except if agreed to by the Sponsor.', 'The participant has a medical condition or personal circumstance that, in the opinion', 'of the investigator and/or Sponsor, places the participant at unnecessary risk from', 'continued administration of the study intervention.', 'The participant has a confirmed positive serum pregnancy test.', 'The participant has intercurrent illness that prevents further administration of', 'treatment.', 'The participant has any progression or recurrence of any malignancy or occurrence of', 'another malignancy that requires active treatment. Exceptions to malignancy include', 'basal cell carcinoma of the skin, squamous cell carcinoma of the skin, new', 'nonulcerated primary melanoma <1 mm in depth with no nodal involvement, or', 'carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone', 'potentially curative therapy. Exceptions should be discussed with the Sponsor before', 'continuing therapy or remaining in follow-up.', 'The participant has unacceptable AE(s) or toxicities.', 'Any study intervention-related toxicity specified as a reason for permanent', 'discontinuation as defined in the guidelines for dose modification due to AEs in', 'Section 6.6.', '7.1.1', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study.', '7.2', 'Participant Withdrawal From the Study', \"A participant must be withdrawn from the study if the participant or participant's legally\", 'acceptable representative withdraws consent from the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}